New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement

Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR

“Polypill” Reduces Cardiovascular Mortality by 33 Percent in Patients Treated After a Heart Attack

A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.

Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement

Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial